Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
0
1
1
0
0
Turnstone Biologics Corp. - Common Stock
Share · US90042W1009 · TSBX (XNAS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Turnstone Biologics Corp. - Common Stock
Analyst Grade Summary
No Price
Share Float & Liquidity
Free Float 74,46 %
Shares Float 17,23 M
Shares Outstanding 23,14 M
Company Profile for Turnstone Biologics Corp. - Common Stock Share
Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.
Company Data
Name Turnstone Biologics Corp. - Common Stock
Company Turnstone Biologics Corp.
Symbol TSBX
Website
https://turnstonebio.com
Primary Exchange 
NASDAQ
NASDAQ
ISIN US90042W1009
Asset Class Share
Sector Healthcare
Industry Biotechnology
CEO Sammy J. Farah
Country United States of America
Currency USD
Employees 0,0 T
Address 9310 Athena Circle, 92037 LA Jolla
IPO Date 2023-07-21
Ticker Symbols
| Name | Symbol |
|---|---|
| NASDAQ | TSBX |
More Shares
Investors who hold Turnstone Biologics Corp. - Common Stock also have the following shares in their portfolio:
